Merck Animal Health Collaborates with AmacaThera to Develop Long-Acting Injectable Formulations for Veterinary Use
Shots:
- Merck Animal Health has entered into a binding evaluation & option agreement with AmacaThera to develop long-acting formulations for veterinary use
- Collaboration will leverage AmacaThera’s AmacaGel hydrogel platform to develop single-injection veterinary therapeutics with enhanced sustained drug delivery
- AmacaGel is a fast-gelling hydrogel composed of 2 established polymers, designed to liquefy under shear force for easy delivery via conventional syringe, which rapidly forms a drug depot upon warming to body temperature
Ref: Prnewswire | Image: Merck Animal Health & AmacaThera
Related News:- Merck Animal Health Receives the EC’s Approval of BRAVECTO TriUNO for Use in Dogs
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
